What is Sareum?
Sareum is dedicated to advancing novel therapeutics by focusing on the TYK/JAK kinase cell signaling family. The company's core strategy involves developing small molecules that target the TYK2/JAK1 space, aiming for superior efficacy through dual kinase inhibition. Their pipeline is advancing, with lead asset SDC-1801 poised for Phase 2 development, signaling a critical juncture in their research and development efforts to create best-in-class treatments.
How much funding has Sareum raised?
Sareum has raised a total of $6.3M across 1 funding round:
Private Equity
$6.3M
Private Equity (2023): $6.4M with participation from Riverfort Global Opportunities
Key Investors in Sareum
Riverfort Global Opportunities
Riverfort Global Opportunities is an investment firm with a focus on special situations and unlisted/pre-IPO opportunities, suggesting a strategic interest in Sareum's development stage.
What's next for Sareum?
The recent major enterprise-level funding provides Sareum with substantial resources to accelerate its pipeline development and clinical trials. This strategic investment is expected to fuel the progression of SDC-1801 and potentially other pipeline candidates, positioning Sareum to further explore the therapeutic potential of kinase inhibition in oncology and autoimmune indications. The company's focus on dual JAK kinase inhibition represents a key differentiator in a competitive therapeutic landscape.
See full Sareum company page
